Chronic Lymphocytic Leukemia News and Research RSS Feed - Chronic Lymphocytic Leukemia News and Research

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding.
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML). [More]
New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

In humans the differentiation of stem cells into hundreds of specialized cell types is vital. Differentiation drives development from fertilized egg to a newborn, and it underlies the continuous replacement of the 5 billion cells that die every hour in an adult. On the downside, mutations in differentiation pathways of different cell types can be drivers of cancers. [More]
Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults. [More]
ICGC article lays foundation for the coming era of cancer genomic research

ICGC article lays foundation for the coming era of cancer genomic research

An eye-opening article from the International Cancer Genome Consortium was published today in the prestigious journal Nature Communications. It lays a foundation for the coming era of research in cancer genomics. [More]
NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil. [More]
Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer. [More]
Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. [More]
Analysis of high-throughput sequencing data reveals new genes linked to chronic lymphocytic leukemia

Analysis of high-throughput sequencing data reveals new genes linked to chronic lymphocytic leukemia

Johannes Reiter, former PhD student in the group of Krishnendu Chatterjee at the Institute of Science and Technology Austria (IST Austria), is co-author of a Nature paper on genetic alterations that drive the progression and relapse of cancer. [More]
Researchers develop promising metal-based compound to fight kidney cancer

Researchers develop promising metal-based compound to fight kidney cancer

Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life. [More]
Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center. [More]
Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas. [More]
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
New treatment option available for CLL patients in Manitoba and Saskatchewan

New treatment option available for CLL patients in Manitoba and Saskatchewan

People in Manitoba and Saskatchewan living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the prescription drug insurance plans in both provinces. Earlier this week, GAZYVA (obinutuzumab) in combination with chlorambucil chemotherapy was added to benefits formularies of the Provincial Oncology Drug Programs at CancerCare Manitoba and the Saskatchewan Cancer Agency. [More]
Advertisement